Matching Patients to Multiple Concurrent Trials Automation

Manual screening requires coordinators to check each patient against one trial at a time, a process that consumes 4-8 hours per patient and creates enrollment lag. A custom workflow uses parallel agentic screening to evaluate a patient's EHR, genomic, and narrative data against all open trial protocols simultaneously, pre-qualifying candidates in minutes. This shifts human effort from repetitive checking to high-value review of machine-generated shortlists.

A patient eligible for multiple studies is typically only matched to the first protocol a coordinator reviews, leaving potential enrollment slots unfilled. The multi-trial workflow identifies all viable study opportunities for a patient, ranking them by fit and site feasibility. This maximizes patient choice and site throughput, directly increasing the number of patients enrolled per screening cycle and improving overall trial fill rates.

Manually managing a patient across multiple concurrent trials risks protocol conflicts and accidental duplicate enrollment, a major operational and compliance hazard. The custom workflow architecture includes a centralized conflict-checking agent that evaluates eligibility overlap, visit scheduling clashes, and pharmacovigilance rules across all matched trials. It enforces governance by recommending the optimal single trial or flagging conflicts for human arbitration before consent.

The slow drip of manual patient finding is the primary driver of delays between site activation and First Patient First Visit (FPFV). By automating parallel screening, sites can process their entire pre-identified patient backlog within days of activation. This compresses the enrollment ramp-up phase, getting trials to critical milestones faster and reducing costly site idle time.

Sponsor and IRB audits require clear rationale for why a patient was matched or excluded from a trial. Manual notes are inconsistent and incomplete. This workflow embeds an explainability layer that logs every data point evaluated, the rule or model applied, and the resulting eligibility score for each trial. Automated reports provide ready-made, defensible documentation for regulatory review, reducing audit preparation from days to hours.

Clinical sites are paid per enrolled patient. Manual screening limits the number of patients they can match, capping revenue potential. This automated matching engine transforms a site's EHR data into a scalable, high-throughput enrollment asset. By matching more patients to more trials faster, sites significantly increase their grant revenue per clinician FTE, improving the economic model of clinical research participation.

The core of the workflow is an orchestrated pool of specialized screening agents. Each agent is configured with the logic for a specific trial's inclusion/exclusion criteria, including complex temporal rules and biomarker requirements. Using a framework like LangGraph, these agents operate in parallel against a unified patient data model pulled from EHR (Epic, Cerner), genomic pipelines, and clinical narratives, delivering a complete match matrix in minutes instead of the hours or days of sequential manual checks.

When a patient qualifies for multiple concurrent trials, a rules-based arbitration agent automatically evaluates conflicts (e.g., overlapping visit schedules, incompatible treatments) and applies sponsor-defined priority logic (e.g., trial phase, enrollment urgency, therapeutic focus). This layer prevents operational deadlocks and generates a ranked shortlist of recommended studies for discussion with the patient, turning a complex manual coordination task into a governed, auditable decision.

Before any patient data is evaluated, a governance agent checks active consent forms and Data Use Agreements (DUAs) against the requested protocol criteria. Only consented data elements are released to the screening engine. Every data access, matching decision, and conflict resolution is logged to an immutable audit trail with full explainability, creating a defensible record for IRB review and regulatory inspection (HIPAA, GDPR).

The workflow integrates with Clinical Trial Management Systems (CTMS) like Veeva Vault to automatically check site activation status, enrollment caps, and principal investigator sub-specialties. A matched patient is only presented for studies at sites that are ready to enroll and have appropriate capacity, eliminating wasted screening effort and accelerating the path from identification to first visit.

Matches are not auto-enrolled. The workflow routes ranked opportunities, with supporting evidence, into a physician review queue within the EHR or a dedicated portal. Upon approval, an outreach orchestration agent triggers personalized patient communications (via patient portal, SMS, or integrated CRM) and can initiate a digital pre-screening or eConsent workflow, creating a seamless handoff from discovery to engagement.

Operational dashboards track key metrics: match rates, screen-to-consent conversion, protocol complexity scores, and algorithm performance across demographics. Drift detection agents monitor for declining match accuracy, triggering retraining of NLP extraction models or adjustment of screening logic. This closed-loop control ensures the workflow adapts to new trial designs and evolving real-world data patterns.

The core governance layer is an orchestration agent that applies business rules to resolve conflicts when a patient qualifies for multiple trials. It evaluates protocol priority (e.g., phase, sponsor contract), therapeutic urgency, and geographic feasibility to recommend an optimal primary match, while flagging secondary options for site discussion. This logic prevents operational chaos and ensures strategic enrollment decisions are automated and reproducible.

Automated workflows must manage granular, time-bound patient consents. An agent monitors the consent registry and, upon a new match, checks if existing broad consent applies or triggers a site-to-patient re-permissioning workflow via integrated eConsent platforms. All consent states are immutably logged against patient and trial IDs, creating a clear chain of permission essential for protocol adherence and audit defense.

Every automated eligibility flag—whether from NLP phenotype extraction or genomic variant matching—must generate an audit-ready explanation report. A dedicated governance agent retrieves the source data snippets, model confidence scores, and applied rule logic to synthesize a human-readable rationale for each match or exclusion. This report is attached to the patient's profile in the CTMS, building essential trust with investigators and reviewers.

A background monitoring agent runs continuous statistical checks on the output of screening algorithms, measuring match rates across demographic subgroups (age, gender, race, ZIP code). It alerts study managers to unintended skew and can trigger a review-and-retrain cycle for the underlying models. This proactive governance is critical for ensuring equitable trial access and preempting regulatory challenges related to cohort diversity.

All actions—data queries from EHRs, algorithm executions, consent checks, and user overrides—are logged to an immutable, time-series database (e.g., using a blockchain-like ledger or write-once storage). A separate reporting agent can automatically assemble these logs into inspection-ready packages for a specific patient or trial, providing regulators with a complete, tamper-evident record of the automated matching lifecycle.

Governance is enforced through mandatory HITL checkpoints before any irreversible action. Key gates include: physician sign-off on final match recommendations, site coordinator approval for patient contact, and pharmacovigilance review for SAE history flags. The workflow orchestrator (e.g., LangGraph) manages these states, routing tasks to the appropriate role in the CTMS or email and halting progression until approval is digitally captured.